Loading...
Market
Story
New Immunotherapy Drug Could Triple Survival Rates, Replace Surgery for Bowel Cancer
Jun 2, 2024, 06:31 PM
A new immunotherapy drug that 'melts away' tumors could revolutionize the treatment of bowel cancer, potentially replacing surgery. Doctors have hailed the drug as a 'gamechanger,' with a key trial showing it to be more than ten times as effective as conventional treatments. The drug, already available on the NHS, could save hundreds of lives annually in the UK by tripling survival rates for a deadly type of bowel cancer. The promising results from the trial suggest that the drug could significantly improve patient outcomes and reduce the need for invasive surgical procedures.
View original story
Similar markets
Less than 25% • 25%
25-49% • 25%
50-74% • 25%
75% or more • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less effective • 25%
Equally effective • 25%
1-2 times more effective • 25%
More than 2 times more effective • 25%
Less than 1000 • 25%
1000 to 5000 • 25%
5000 to 10000 • 25%
More than 10000 • 25%
Less than 5 • 25%
5 to 9 • 25%
10 to 14 • 25%
15 or more • 25%
0-5 • 20%
6-10 • 20%
11-15 • 20%
16-20 • 20%
More than 20 • 20%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Backlog reduced by 50% • 33%
Backlog reduced by 25% • 33%
No significant reduction • 34%
Increase by more than 5% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Decrease • 25%